Amylyx Pharmaceuticals (AMLX) Receivables (2022 - 2025)

Amylyx Pharmaceuticals' Receivables history runs 4 years deep, the most recent figure standing at $188000.0 for Q4 2025.

• In Q4 2025, Receivables fell 65.63% year-over-year to $188000.0; the TTM figure through Dec 2025 stood at $188000.0 (down 65.63% YoY), while the FY2025 annual figure was $188000.0, down 65.63% from the prior year.
• Receivables was $188000.0 for Q4 2025 at Amylyx Pharmaceuticals, down from $232000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $40.6 million in Q4 2023 to a low of $137000.0 in Q3 2022.
• Historically, Receivables has averaged $11.9 million across 4 years, with a median of $3.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Receivables jumped 21398.54% in 2023, then slumped 98.65% in 2024.
• A 4-year view of Receivables shows it stood at $15.8 million in 2022, then soared by 156.55% to $40.6 million in 2023, then plunged by 98.65% to $547000.0 in 2024, then slumped by 65.63% to $188000.0 in 2025.
• The last three Receivables figures came in at $188000.0 (Q4 2025), $232000.0 (Q3 2025), and $203000.0 (Q2 2025), per Business Quant data.